Nanoplasmonics-based molecular analysis tool for molecular biomarkers of cancer

基于纳米等离子体的癌症分子生物标志物分子分析工具

基本信息

批准号：
9321908
负责人：
Tuan Vo-Dinh
金额：
$ 23.7万
依托单位：
DUKE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2015
资助国家：
美国
起止时间：
2015-09-08 至 2018-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9321908
关键词：
Adopted Area Barrett Esophagus Biological Assay Biological Markers Biological Models Biosensing Techniques Blood Blood specimen Clinic Clinical Competitive Binding Consumption DNA Detection Development Diagnosis Diagnostic Diagnostic tests Early Diagnosis Early Intervention Endoscopy Enrollment Esophageal Esophageal Adenocarcinoma Excision Future Goals Gold Human Incidence Investigation Label Malignant Neoplasms Malignant neoplasm of esophagus Malignant neoplasm of gastrointestinal tract Methods MicroRNAs Molecular Molecular Analysis Molecular Conformation Nanotechnology Northern Blotting Patients Polymerase Chain Reaction Process Research Resources Reverse Transcriptase Polymerase Chain Reaction Reverse Transcription Risk Risk Factors Sampling Scheme Screening for cancer Sentinel Shapes Signal Transduction Specificity Surface System Systems Analysis Techniques Technology Testing Time Tissues Translating accurate diagnosis anticancer research base cancer biomarkers cancer diagnosis cancer type clinical Diagnosis clinical diagnostics clinical practice clinical risk clinical translation cohort cost cost effective design diagnosis standard diagnostic accuracy diagnostic screening gastrointestinal improved innovation interest laboratory equipment microRNA biomarkers minimally invasive molecular marker multiplex detection nanoplasmonic nanoprobe new technology new therapeutic target novel novel diagnostics novel strategies peripheral blood plasmonics point of care public health relevance repository screening small molecule stem surveillance strategy tool

项目摘要

DESCRIPTION (provided by applicant): MicroRNAs (miRNAs) have demonstrated great promise as biomarkers for investigation of cancer development and progression and for early detection, yet these small molecules have not been adopted into early diagnostics for clinical practice because of challenging analytical aspects in the lab. Microarray-based technology, Northern blotting, sequencing, and qRT-PCR analyses are often employed, involving elaborate, time-consuming and expensive processes that require special laboratory equipment. There is a need to develop alternative molecular assay strategies that may offer more advantages over conventional methods and have the potential to enhance research in the areas of early detection and screening, and clinical diagnosis. Although miRNAs related to gastrointestinal (GI) cancer will be used as the model system, the proposed molecular analysis technology will be applicable generally to other types of cancers and other miRNA probes. We will develop a novel molecular analysis technology based on the "Inverse Molecular Sentinel" (iMS) scheme using surface-enhanced Raman scattering (SERS) detection that will move miRNA testing from an RT-PCR lab-based based assay scheme to a molecular analysis and testing technology that is simpler, faster and more cost effective. The specific aims of this project are: (1) Develop the new iMS molecular analysis method for multiplex detection of molecular biomarkers, miRNAs. Due to the highly specific and narrow SERS peaks, we will use the iMS technique to simultaneously detect multiple microRNA sequences as a simple and rapid multiplex screening tool for esophageal cancer. The analytical features of merit (specificity, sensitivity, probe stability) of the new molecular analysis technology will be investigated in detail. (2) Apply and evaluate the iMS molecular analysis method for diagnosis and investigation of GI cancer development and progression using clinical samples. We will demonstrate the usefulness of the iMS technique to detect miRNAs in peripheral blood samples from patients with known cancer diagnosis and from controls. In the clinical cohort, RT-PCR will be used as the gold standard for diagnosis, and nanoprobes will be tested against RT-PCR for diagnostic accuracy. The iMS biosensing system has the potential to be faster and more efficient than currently available systems, and is capable of providing great sensitivity with higher levels of specificity and multiplexing capabilities to screen microRNAs associated with Barrett's esophagus and esophageal cancer. In conclusion, the proposed molecular analysis technology represents a major innovation that has great transformative potential in cancer research, diagnostics and screening. The iMS approach is a `homogenous' assay (i.e., requiring no sample removal, and thus no microfluids). Also, the targets do not need to be labeled, thus reducing cost and complexity. The advantages of the novel molecular analysis technology would allow detection of multiple miRNA biotargets for research on cancer development and progression, and ultimately enable its future clinical translation to render a faster and more accurate diagnosis at point-of-care settings.

描述（由适用提供）：MicroRNA（miRNA）表现出了巨大的希望，这是用于投资癌症发展和进展以及早期检测的生物标志物，但是由于实验室中的挑战者方面，这些小分子尚未被用于临床实践的早期诊断。通常采用基于微阵列的技术，北印迹，测序和QRT-PCR分析，涉及需要特殊实验室设备的精心制作，耗时且昂贵的过程。有必要制定替代性分子测定策略，这些策略可能比传统方法具有更多优势，并有可能增强对早期检测和筛查领域以及临床诊断方面的研究。尽管与胃肠道（GI）癌症有关的miRNA将用作模型系统，但拟议的分子分析技术通常适用于其他类型的癌症和其他miRNA问题。我们将使用表面增强的拉曼散射（SERS）检测来开发一种新型的分子分析技术（IMS逆哨兵）（IMS）方案，该方案将将miRNA测试从基于RT-PCR实验室的测定方案转移到分子分析和测试技术更简单，更快，更快，更具成本效益。该项目的具体目的是：（1）开发新的IMS分子分析方法用于分子生物标志物miRNA的多重检测。由于高度特异性和狭窄的SERS峰，我们将使用IMS技术同时检测多个microRNA序列，作为食管癌的简单而快速的多重筛选工具。新分子分析技术的功绩，特异性，灵敏度，探针稳定性的分析特征将进行详细研究。（2）使用临床样本应用和评估IMS分子分析方法进行诊断和研究胃肠癌的发展和进展。我们将证明IMS技术在检测已知癌症诊断患者和对照组的外周血样本中检测miRNA的有用性。在临床队列中，RT-PCR将用作诊断的黄金标准，纳米探针将针对RT-PCR进行测试以诊断精度。 IMS生物传感系统具有比当前可用的系统更快，更有效的潜力，并且能够提供具有更高水平的特异性和多重能力的敏感性，以筛选与Barrett的食管和食管癌相关的microRNA。总之，提出的分子分析技术代表了一项主要创新，在癌症研究，诊断和筛查中具有巨大的变革潜力。 IMS方法是一种“同质”测定法（即需要除去样品，因此没有微流体）。同样，目标不需要标记，从而降低了成本和复杂性。新型分子分析技术的优点将允许检测多个miRNA生物目标进行癌症发展和进展的研究，并最终使其未来的临床翻译能够在护理点环境下更快，更准确的诊断。